Isoniazid
- Generic Name
- Isoniazid
- Brand Names
- Isonarif, Isotamine, Isotamine B, Rifamate, Rifater
- Drug Type
- Small Molecule
- Chemical Formula
- C6H7N3O
- CAS Number
- 54-85-3
- Unique Ingredient Identifier
- V83O1VOZ8L
- Background
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
- Indication
Isoniazid is used for the treatment of all forms of tuberculosis in which organisms are susceptible. It is also used in combination with rifampin and pyrazinamide.
- Associated Conditions
- Active Tuberculosis, Mycobacterium kansasii infection, Late phase Tuberculosis
Risk of SDRs Under 3HP and 1HP Regimen for LTBI
- First Posted Date
- 2019-09-18
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 490
- Registration Number
- NCT04094012
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care
- Conditions
- TuberculosisPre-XDR-TBExtensively Drug-Resistant TuberculosisMulti Drug Resistant TuberculosisRifampicin Resistant Tuberculosis
- Interventions
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Wits Health Consortium (Pty) Ltd
- Target Recruit Count
- 402
- Registration Number
- NCT04062201
- Locations
- 🇿🇦
Jose Pearson TB Hospital, Port Elizabeth, Eastern Cape, South Africa
🇿🇦King DinuZulu Hospital Complex, Durban, KwaZulu Natal, South Africa
A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2023-10-23
- Target Recruit Count
- 24
- Registration Number
- NCT03891901
- Locations
- 🇺🇸
Emory University DAIDS TB Non-Network CRS, Atlanta, Georgia, United States
Doravirine, Rifapentine and Isoniazid Interaction
- Conditions
- Rifamycins Causing Adverse Effects in Therapeutic UseDrug Interaction PotentiationLatent TuberculosisHuman Immunodeficiency Virus
- Interventions
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Walter K. Kraft
- Target Recruit Count
- 11
- Registration Number
- NCT03886701
- Locations
- 🇺🇸
Thomas Jefferson University Clinical Research Unit, Philadelphia, Pennsylvania, United States
Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis
- First Posted Date
- 2018-12-27
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 676
- Registration Number
- NCT03787940
- Locations
- 🇨🇳
Jiangxi Provincial Chest Hospital, Nanchang, China
🇨🇳Zunyi Medical College affiliated Hospital, Zunyi, China
🇨🇳Jiamusi Infectious Disease Hospital, Jiamusi, China
Video Based Directly Observed Therapy for Latent TB
- Conditions
- Latent Tuberculosis
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2019-07-01
- Lead Sponsor
- St. Louis University
- Registration Number
- NCT03783728
- Locations
- 🇺🇸
Saint Louis University, Saint Louis, Missouri, United States
Tuberculosis Clinical Trials Consortium Study 35
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 72
- Registration Number
- NCT03730181
- Locations
- 🇿🇦
Desmond Tutu TB Center, University of Stellenbosch, Stellenbosch, South Africa
A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status
- Conditions
- Drug-Induced Liver InjuryAdverse Drug EventTuberculosis
- Interventions
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT03665402
- Locations
- 🇰🇷
Seoul National University Hospital Clinical Trials Center, Seoul, Korea, Republic of
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
- Conditions
- Tuberculosis, MDR
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2025-04-23
- Target Recruit Count
- 5834
- Registration Number
- NCT03568383
- Locations
- 🇧🇼
Gaborone CRS, Gaborone, South-East District, Botswana
🇧🇷Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro, Brazil
🇭🇹GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS, Port-au-Prince, Haiti
Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-08-13
- Target Recruit Count
- 51
- Registration Number
- NCT03510468
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.